• Weilin Xu, Liansheng Gao, Tao Li, Anwen Shao, and Jianmin Zhang.
• Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
• Curr Neuropharmacol. 2018 Jan 1; 16 (9): 1296-1305.

BackgroundNeurological diseases have always been one of the leading cause of mobility and mortality world-widely. However, it is still lacking efficient agents. Agmatine, an endogenous polyamine, exerts its diverse biological characteristics and therapeutic potential in varied aspects.MethodsThis review would focus on the neuroprotective actions of agmatine and its potential mechanisms in the setting of neurological diseases.ResultsNumerous studies had demonstrated the neuroprotective effect of agmatine in varied types of neurological diseases, including acute attack (stroke and trauma brain injury) and chronic neurodegenerative diseases (Parkinson's disease, Alzheimer's disease). The potential mechanism of agmatine induced neuroprotection includes anti-oxidation, anti-apoptosis, anti-inflammation, brain blood barrier (BBB) protection and brain edema prevention.ConclusionsThe safety and low incidence of adverse effects indicate the vast potential therapeutic value of agmatine in the treatment of neurological diseases. However, most of the available studies relate to the agmatine are conducted in experimental models, more clinical trials are needed before the agmatine could be extensively clinically used.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

16 keywords...

hide…